Wall Street is hopeful that a pipeline of cancer drugs can drive earnings growth as the respiratory vaccine business ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, ...

In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

The vaccine maker is expanding beyond its COVID-focused offerings.

Moderna Inc.’s chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

In the latest close session, Moderna (MRNA) was down 1.48% at $47.99. The stock fell short of the S&P 500, which registered a gain of 0.5% for the day. Elsewhere, the Dow gained 0.64%, while the ...

We learn what the findings could mean for fighting cancer ...

Moderna chief executive officer Stephane Bancel said the company does not plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from health officials in the ...

Jan 22 (Reuters) - Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to ...

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...